Loading…
Atrium Therapeutics, Inc. is projected to rise to $13.26 by 2027, a +5% move from its current price of $12.60. RNA is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/11/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $12.33 | $12.60 | $12.87 | 0.00% |
| Jul 14 | $12.22 | $12.60 | $12.99 | +0.01% |
| Jul 15 | $12.14 | $12.60 | $13.08 | +0.01% |
| Jul 16 | $12.07 | $12.60 | $13.15 | +0.01% |
| Jul 17 | $12.01 | $12.60 | $13.22 | +0.01% |
| Jul 18 | $11.96 | $12.60 | $13.28 | +0.02% |
| Jul 19 | $11.91 | $12.60 | $13.34 | +0.02% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $11.91 | $12.60 | $13.34 | +0.02% |
| Week 2 | $11.63 | $12.60 | $13.66 | +0.04% |
| Week 3 | $11.43 | $12.61 | $13.91 | +0.06% |
| Week 4 | $11.26 | $12.61 | $14.13 | +0.07% |
| Week 5 | $11.11 | $12.61 | $14.32 | +0.09% |
| Week 6 | $10.98 | $12.61 | $14.50 | +0.11% |
| Week 7 | $10.86 | $12.62 | $14.66 | +0.13% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Atrium Therapeutics, Inc., a healthcare biopharmaceutical company, focuses on delivering ribonucleic acid (RNA) therapeutics to the heart to transform the care for people living with cardiomyopathies. Its development stage product candidates include ATR 1072, a siRNA-based therapy targeting PRKAG2 for the treatment of PRKAG2 syndrome; and ATR 1086, a siRNA-based therapy targeting PLN for the treatment of PLN cardiomyopathy. The company was incorporated in 2025 and is headquartered in San Diego, California.
Atrium Therapeutics, Inc. trades under the symbol RNA and has a current price of $13.19. Its market capitalization is $225.62M and its market rank is 3725. The price outlook is informed by a year-by-year forecast that projects higher averages in coming years, with a max forecast of $117.85 and an avg forecast of $62.78 by 2050.
A major floor 17.0% below — a decisive break under it would weaken the trend.
The nearest floor, 8.3% below — buyers have tended to step in here.
The nearest ceiling, 8.3% above — a clean break opens room to run.
A major ceiling 31.3% above — clearing it would confirm fresh momentum.
Key RNA support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of RNA market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $13.00 | Sell | $12.93 | Sell |
| MA 10 | $13.22 | Sell | $13.02 | Sell |
| MA 20 | $12.94 | Sell | $12.96 | Sell |
| MA 50 | $12.85 | Sell | $13.00 | Sell |
| MA 100 | — | Neutral | — | Neutral |
| MA 200 | — | Neutral | — | Neutral |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 43.58 | Neutral |
| Stoch RSI (14) | 0.00 | Buy |
| CCI (20) | -97.76 | Neutral |
| Williams %R (14) | -100.00 | Info |
| MACD (12,26,9) | -0.03 | Sell |
| ROC (12) | -2.73 | Sell |
| Bollinger %B (20,2) | 0.19 | Neutral |
| Stochastic %K (14) | 0.00 | Buy |
| TRIX (15) | 0.13 | Buy |
| Awesome (5,34) | 0.24 | Buy |
| Ultimate (7,14,28) | 37.04 | Neutral |
| Momentum (10) | -0.32 | Sell |
| Aroon Osc (25) | 68.00 | Buy |
| Hull MA (9) | 12.86 | Sell |
| ADX (14) | 11.97 | Neutral |
| ATR (14) | 0.28 | Info |
The 30-day technical picture is bullish. RSI14 is 50 and the 50-day simple moving average is $12.95.
Key near-term levels include support at $11.55 and resistance at $13.36, with a 30-day price range of $11.64 to $14.95. Annualized volatility is 40%.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $11.55 | $12.60 | $15.46 | 0% | Neutral | |
| $10.38 | $13.26 | $18.02 | +5% | Neutral | |
| $11.13 | $14.70 | $20.85 | +17% | Neutral | |
| $12.86 | $17.46 | $25.60 | +39% | Bullish | |
| $13.32 | $18.55 | $27.95 | +47% | Bullish | |
| $12.86 | $18.31 | $28.28 | +45% | Bullish | |
| $13.38 | $19.47 | $30.71 | +55% | Bullish | |
| $13.73 | $20.38 | $32.78 | +62% | Bullish | |
| $14.97 | $22.64 | $37.08 | +80% | Bullish | |
| $16.85 | $25.95 | $43.21 | +106% | Bullish | |
| $20.59 | $34.49 | $61.55 | +174% | Bullish | |
| $30.00 | $58.26 | $114.86 | +362% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $11.55 | $12.60 | $15.12 | +0.00% |
| August 2026 | $10.50 | $12.45 | $15.22 | -1.16% |
| September 2026 | $10.56 | $12.63 | $15.63 | +1.42% |
| October 2026 | $10.63 | $12.80 | $16.01 | +1.34% |
| November 2026 | $10.27 | $12.45 | $15.72 | -2.71% |
| December 2026 | $9.96 | $12.14 | $15.46 | -2.49% |
Click any year to see its month-by-month RNA forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
By 2026, RNA could reach as high as $15.46, with a base case around $12.60 and support toward $11.55 — roughly 0% from $12.60. Price action looks broadly range-bound.
Expect RNA to range from $10.38 to $18.02 through 2027. The $13.26 average target implies a +5% move from current prices. That is up +5% on the projected 2026 average. A consolidation phase looks the most probable path here.
The RNA price prediction for 2028 points to an average of $14.70 (low $11.13, high $20.85) — a potential gain of +17% on today's $12.60. Price action looks broadly range-bound.
In 2029, RNA is projected to trade between $12.86 and $25.60, averaging $17.46 — a potential gain of +39% from today's $12.60. That is up +19% on the projected 2028 average. Buyers look set to stay in control over this stretch.
Atrium Therapeutics, Inc.'s 2030 outlook centres on $18.55, within a $13.32 to $27.95 range. That is up +6% on the projected 2029 average. That marks a +47% change versus current levels. Momentum favours further upside here.
By 2031, RNA could reach as high as $28.28, with a base case around $18.31 and support toward $12.86 — roughly +45% from $12.60. Buyers look set to stay in control over this stretch.
Expect RNA to range from $13.38 to $30.71 through 2032. The $19.47 average target implies a +55% move from current prices. That is up +6% on the projected 2031 average. Momentum favours further upside here.
The RNA price prediction for 2033 points to an average of $20.38 (low $13.73, high $32.78) — a potential gain of +62% on today's $12.60. Buyers look set to stay in control over this stretch.
In 2034, RNA is projected to trade between $14.97 and $37.08, averaging $22.64 — a potential gain of +80% from today's $12.60. That is up +11% on the projected 2033 average. Momentum favours further upside here.
Atrium Therapeutics, Inc.'s 2035 outlook centres on $25.95, within a $16.85 to $43.21 range. That is up +15% on the projected 2034 average. That marks a +106% change versus current levels. Buyers look set to stay in control over this stretch.
By 2040, RNA could reach as high as $61.55, with a base case around $34.49 and support toward $20.59 — roughly +174% from $12.60. Momentum favours further upside here.
Expect RNA to range from $30.00 to $114.86 through 2050. The $58.26 average target implies a +362% move from current prices. That is up +69% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in RNA today (≈ 79.365079 RNA) could be worth
$4,623.63
+$3,623.63 (+362%) by 2050 · US Dollar
Based on the average projected RNA price of $58.26 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in RNAwould be worth at today's price.
$1,000 invested in RNA on Feb 27, 2026 (≈ 67.79661 RNA) would be worth
$854.24
-$145.76 (-14.6%) today · 0.85× · US Dollar
Based on a RNA entry price of $14.75 vs. today's $12.6.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $13.65 | $923.08 | -7.7% |
| 1 month ago | $11.67 | $1,079.69 | +8.0% |
| 3 months ago | $12.71 | $991.35 | -0.9% |
| All time ago | $14.75 | $854.24 | -14.6% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our RNA forecast.
Our base-case forecast reaches $25.00 around 2035.
Implied market cap at $25.00: $427.64M
The multi-year forecast shows growth from a 2026 average of $13.19 with neutral sentiment to stronger upside in later years. The forecast lists 2026 min $11.55, avg $13.19, max $16.14 (ROI 0) and 2027 avg $14.09 (ROI 6.8), 2028 avg $15.52 (ROI 17.7).
From 2029 onward the outlook turns bullish, with 2029 avg $18.59 (ROI 40.9) and 2030 avg $19.67 (ROI 49.1). The path continues higher through 2031 $19.20, 2032 $20.92, 2033 $21.78, 2034 $23.86, and 2035 $28.07, all labeled BULLISH with rising ROIs up to 112.8% by 2035. By 2040 the avg is $36.89 (ROI 179.7) and by 2050 it reaches $62.78 (ROI 375.9).
These are estimates, not guarantees, and actual results depend on market conditions and the progress of therapies.
Tap a question to reveal the answer.
The forecast shows an avg price of $19.67 with a 49.1 (bullish) ROI by 2030.
Forecasts show neutral sentiment in 2026-2028 and bullish sentiment from 2029 onward, with an avg price of $18.59 in 2029 and $62.78 by 2050, though these are estimates and not guarantees.
The max forecast by 2050 is $117.85, so reaching $100 is within the projected range, but not guaranteed.
Current price is $13.19 and market capitalization is $225.62M.
The 30-day range is $11.64 to $14.95, with support at $11.55 and resistance at $13.36; RSI is 50 and the 50-day SMA is $12.95.
Atrium Therapeutics, Inc. Community Discussion
0Share your Atrium Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.